Humanized variable domain of heavy chain (VHH) antibodies cross-neutralizing interleukins il-17a and il-17f
Humanized VHH antibodies with high affinity and thermostability address the limitations of systemic IL-17 neutralizing antibodies by enabling local administration and effective targeting of IL-17A and IL-17F, improving treatment efficacy and safety for inflammatory disorders.
Patent Information
- Application Number
- PCT/EP2026/063106
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing IL-17 neutralizing antibodies are systemically administered, leading to potential side effects and are not suitable for topical application, and there is a need for humanized VHH antibodies that can effectively target both IL-17A and IL-17F while minimizing immunogenicity and aggregation.
Humanized VHH antibodies designed with detailed structural knowledge to maintain high affinity and thermostability, allowing local administration and targeting IL-17A and IL-17F, with specific amino acid substitutions and formats such as monovalent or multivalent Fc-fusions.
The humanized VHH antibodies exhibit high affinity and thermostability, reducing systemic side effects and enabling effective treatment of inflammatory and autoimmune disorders, particularly mild to moderate plaque psoriasis, with improved safety and convenience.
Smart Images

Figure IMGF000052_0001_TABLE 
Figure IMGF000052_0002_TABLE 
Figure IMGF000053_0001_TABLE
Abstract
Description
[0001] HUMANIZED VARIABLE DOMAIN OF HEAVY CHAIN (VHH) ANTIBODIES CROSS-NEUTRALIZING INTERLEUKINS IL-17A AND IL-17F
[0002] FIELD OF THE INVENTION
[0003] The present invention pertains in the fields of antibody technology, medicine, and pharmacology. More specifically, the present disclosure provides humanized variable domain of heavy chain (VHH) antibodies that neutralize the pro-inflammatory interleukins IL-17A and IL-17F.
[0004] BACKGROUND OF THE INVENTION
[0005] Interleukin 17 (IL- 17) is a multifunctional cytokine. It is produced by a specific subclass of CD4-positive T helper cells, i.e., Thl7 cells, but also by other CD4- or CD8-positive T cells and gamma / delta T cells. A major effect of IL-17 consists of the attraction of neutrophils and monocytes, and the production of additional cytokines and chemokines by its target cells. Taken together, IL-17 is a key mediator of inflammatory responses. These responses can be of strong benefit to a patient, e.g., when building a defense against various types of infections (Mills, 2022). However, excessive or uncontrolled production of IL- 17 can also provoke or exacerbate autoimmune diseases such as psoriasis, rheumatoid arthritis, asthma, or inflammatory bowel diseases.
[0006] Upstream signaling pathways tightly control the synthesis and secretion of IL- 17 upon mucosal infections. Most notably, Interleukin 23 (IL-23) and IL-1 beta, released from activated dendritic cells or macrophages, stimulate Thl7 cells to release IL-17.
[0007] Target cells of IL-17 can vary since IL-17 receptors are found in a wide array of human cell types. Accordingly, the response can be heterogeneous, too. Most importantly, however, IL-17-exposed epithelial cells release chemokines such as CXCL1 and CXCL8, thereby attracting neutrophilic granulocytes and macrophages to maintain the homeostasis of the epithelial barrier.
[0008] In autoimmune diseases, elevated IL- 17 levels at the site of inflammation activate the release of Interleukin 6 (IL-6), Tumor Necrosis Factor Alpha (TNF-alpha), and matrix metalloproteinases (MMPs). This leads to tissue damage and amplifies the inflammatory response (Mills, 2022).The human genome encodes six IL-17 paralogs, IL-17A through IL-17F. Of these, IL-17A and IL-17F are considered the major and most relevant ones; they are also the best-studied ones. They form homodimers or heterodimers, and they bind to five receptors, IL-17RA-E, and trigger heterodimerization of their receptors. IL-17A and IL-17F bind and activate the IL-17RA and IL-17RC receptors as IL-17A or IL-17F homodimers or as an IL-17A / F heterodimer (Nies and Panzer, 2020). TRAF3IP2 is an essential adapter in IL-17 signaling, promoting the lateral assembly of the receptors. This explains at least partially the onset of intracellular signaling, such as the activation of NF-kappa-B and Mitogen-Activated Protein (MAP) kinases (Wilson et al., n
[0009] A number of approaches were developed to interfere with the production and / or activities of IL-17. In particular, monoclonal antibodies can target the upstream IL-23 but, most importantly, IL-17 itself or its receptor. The neutralization of IL- 17 then dampens the inflammatory response, which is of benefit when treating autoimmune diseases.
[0010] Antagonists to IL-17, particularly antibodies, were successfully applied to treat a number of diseases, giving rise to FDA-approved drugs. Most notably, inflammatory skin diseases, i.e., psoriasis and psoriatic arthritis, as well as hidradenitis suppurativa (“inverse acne”), were treated successfully by IL-17 neutralizing antibodies (summarized in Skroza et al., 2017; Mills, 2022). Therapeutics include ixekizumab and secukinumab that target IL-17A alone in plaque psoriasis (Langley etal., 2014) and psoriatic arthritis (Mease etal., 2015) as well as bimekizumab against both IL-17A and IL-17F in plaque psoriasis (Reich etal., 2021; Warren etal., 2021) and psoriatic arthritis (Glatt et al., 2018).
[0011] However, such antibodies are typically applied systemically, with little or no spatial restriction to the actual sites of inflammation. It should be noted in this context that such indiscriminate block of IL-17 can also exacerbate bacterial or fungal infections as, e.g., reported for bimekizumab (Reich etal., 2021; Warren etal., 2021). Ideally, the neutralization of IL-17, when treating autoimmune diseases, should be locally confined to the site of the disease rather than applied to the whole body. With a more compact, thermostable, and versatile antibody version, topical applications may become feasible.
[0012] As IL- 17 plays a major role in the development of plaque psoriasis, it is the molecular target of several recently launched biological treatments, mainly monoclonal antibodies (mAbs), such as Cosentyx (Novartis) and Taltz (Lilly), both of which target IL- 17A. Research shows that targeting IL-17F in addition to IL-17A provides higher efficacy in treating plaque psoriasis. The recentlylaunched Bimzelx (UCB) was the first mAh targeting both IL-17A and IL-17F to be approved by the European Medicines Agency (EMA). MoonLake Immunotherapeutics developing a 40kD tri-specific humanized nanobody construct targeting IL- 17 A, IL-17F and albumin (sonelokimab), reported superior results vs. Cosentyx in a phase 2 plaque psoriasis clinical trial. All the above-mentioned antibodies, indicated only for moderate to severe psoriasis patients, are administered by subcutaneous injection for systemic drug distribution and carry risk of considerable side effects. These drugs are also expensive as they require chronic, life-long, bi-weekly injections, each at a cost of several thousand dollars. Mild psoriasis, which accounts for 50% of plaque psoriatic patients, unfortunately has no safe and affordable biological drug available. Experience shows that even the 28% of patients with moderate plaque psoriasis tend to avoid or delay onset of these biological treatments due to the associated risks.
[0013] On top of skin diseases, other inflammatory disorders might become amenable to treatment with IL-17 antagonists. These include but are not limited to ankylosing spondylitis (with approved application), but also multiple sclerosis, rheumatoid arthritis, asthma, graft-versus-host disease, and even diseases like Alzheimer's’, fatty liver disease, and COVID-19 (all clinical studies ongoing as reviewed in Mills, 2022). Future applications may consist of the treatment of Parkinson’s disease, atherosclerosis, stroke, and sepsis. Most of these applications will benefit from a more versatile type of antibody with high affinity, stability, and versatility regarding application routes and fusion to additional / stabilizing entities. This illustrates the immense spectrum of benefits expected from VHH antibodies targeting IL-17A / F.
[0014] A complication in antibody therapy is that patients may develop anti-drug antibodies that render the therapeutic antibody eventually ineffective. This is a particular problem when the therapeutic antibody is repeatedly applied, for example during the treatment of a chronic disease. This risk can be reduced and the onset of the anti-drug response delayed by engineering of the therapeutic antibody to have a very low aggregation propensity and a high similarity to human antibodies. The latter includes that fused Fc fragments are chosen from a human origin. However, also the frameworks of the variable domains differ between human and alpacas. Furthermore, affinity maturation often involves mutations in the framework. The resulting deviations from the human germline sequences make also the framework of VHH domains a target of an anti-drug response. Humanization of the VHH should reduce this risk (Rossotti et al., 2022). Humanizing mutations, however, can affect the paratope, change the surface hydrophilicity, and alter the fold and as consequences impair antigen-binding, reduce stability, and increase the aggregation propensity.Humanization is therefore non-trivial and a challenging task. It requires to find the best possible compromise between a maximum of humanization and preservation or even improvement of antigen-binding, stability, and aggregation resistance. This necessitates either to screen a large number of (combined) mutations or to start the humanization project with a detailed knowledge of the paratope, of the burial or exposure of the relevant residues, and the fold of the VHH domain. Nanobodies (variable domain of heavy chain or VHH antibodies) comprise a novel class of therapeutic proteins based on monovalent, camelid-derived heavy-chain-only antibodies (Hamers-Casterman etal., 1993; Arbabi Ghahroudi etal., 1997). In contrast to monoclonal IgGs, which are manufactured in mammalian cells, nanobodies can be produced in bacteria or yeast. Apart from their low molecular weight, certain nanobodies proved to be hyper-thermostable and displayed a particularly high affinity (Guttler et al., 2021).
[0015] One IL-17 antagonist, sonelokimab, was engineered based on single-chain antibodies / nanobodies. It is a trimer of nanobodies targeting IL-17A, IL-17F, and albumin. The idea is to absorb both versions of IL-17 and increase the half-life of the antagonist by binding to albumin. However, this compound, based on its size and albumin-binding entity, is still suitable for systemic rather than topical application. Similar to the classical antibody treatments, the study participants had an increased incidence of fungal Candida infections (Papp etal., 2021).
[0016] WO 2012 / 156219 discloses single domain antibodies that specifically bind to human IL-17A, human IL-17F and / or human IL-17AF, and tandem fusions of them, though the affinity of the individual VHHs to IL-17F was rather weak.
[0017] WO 2024 / 141567 to some of the inventors of the present invention, disclosed alpaca-derived VHH antibodies that cross-react with and neutralize IL-17, particularly human IL-17A homodimers, human IL-17F-homodimers and human IL-17AF heterodimers with high potency. There is a clear unmet need for humanized and improved forms of VHH antibodies that will target both IL-17A and IL-17F and that will be safely used to treat inflammatory, immune, and autoimmune disorders and diseases. Such agents may advantageously be used to treat mild and moderate plaque psoriasis by local administration.SUMMARY OF THE INVENTION
[0018] The present invention provides compositions and methods for the amelioration of symptoms associated with overactivity of the cytokine IL-17 and provides humanized and partially humanized single-domain VHH antibodies that neutralize the human cytokine for treating patients with inflammatory and / or immune-related disorders caused by and / or associated with an overactivity of this cytokine. The humanized VHH antibodies of the present invention possess unexpected improved thermostability and are provided for the treatment of immune, autoimmune, and inflammatory diseases and disorders, including skin diseases and disorders.
[0019] The humanized VHH antibodies of the present invention were designed using information gained from their original alpaca’s sequences, aligned with a specific sequence of a human germline variable heavy chain and from data gained from crystal and modelled structures of complexes of the alpaca’s VHH antibodies and human IL-17 polypeptides. The information on amino acid residues in the VHH molecules that are interacting with IL- 17 and mostly contribute to binding, together with variable heavy chain germline sequence and additional structural information gained from the crystal models were used in the present invention to create humanized VHH antibodies with improved properties. Humanization of anti-IL-17 VHH antibodies, as disclosed in the present application, was not trivial because the detailed knowledge of the structure of the VHH-target complex was required for a rational design. These structures revealed the paratope and how exactly the amino acids pack to each other to generate the specific fold and thus the geometry of this particular VHH antibody. This detailed information allowed testing by computational methods which exchanges are tolerated without deteriorating affinity or stability. The process of humanization disclosed in the present application was a challenging task that solved the problem of finding the best possible compromise between a maximum of humanization and a preservation or even improvement of antigen-binding, stability, and aggregation resistance.In certain embodiments, the humanized VHH antibodies are in monovalent form, e.g., they are produced as a single VHH domain or as a fusion to a heterologous protein such as an immunoglobulin Fc fragment, or serum albumin useable in a wide range of formats. In certain embodiments, the humanized VHH antibodies are in multivalent form, e.g., as bivalent Fc-fusion. The use in a monovalent format is possible due to their very high affinity. In certain embodiments, the humanized VHH antibodies have, in the monovalent format, a target affinity in the picomolar or even low picomolar range. This very high affinity to IL-17 was retained even after humanization, namely substitution of framework amino acid residues. In certain embodiments, the humanized VHH antibodies neutralize human IL-17A and IL-17F with high potency.
[0020] The present invention is based in part on the finding that humanization of specific VHH antibodies resulted unexpectedly not only in preserving and even improving affinities to IL-17A and IL-17F, but also in improvement of thermostability that is crucial for production, storage and use of the anti-IL-17 VHH antibodies in therapy.
[0021] The humanized VHH antibodies of the present invention are designed, according to some embodiments, to be administered locally to the dermis, which may allow the systemic concentration to be kept sufficiently enough to avoid systemic side effects. Humanization not only improves their safety, by rendering them less immunogenic, but also, their improved thermostability may ease their formulation and enable a convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients.
[0022] The present invention provides a humanized or partially humanized VHH antibody that recognizes a human IL- 17 polypeptide and cross-reacts with a plurality of different human IL- 17 polypeptides, comprising (i) a human IL-17A homodimer, (ii) a human IL-17F homodimer, and (iii) a human IL-17AF heterodimer, and that prevents or inhibits activation of a human IL- 17 receptor. The humanized VHH antibodies of the present invention are hyperthermostable and bind with extreme affinity to different IL- 17 paralogs that differ in their epitopes.
[0023] According to some embodiments, the binding affinity of a monomeric humanized or partially humanized VHH antibody, expressed as a dissociation constant KD, to an immobilized human IL-17A is 500 pM, 300 pM, 200 pM, 150 pM, or less. According to some embodiments, the binding affinity of a monomeric humanized VHH, expressed as a dissociation constant KD, to immobilized IL-17F homodimer is 5 nM, 2 nM, 1 nM, 500 pM, 300 pM, or less.The present invention provides a humanized or partially humanized variants of the VHH antibody set forth as SEQ ID NO. 1.
[0024] According to one aspect, the present invention provides a VHH antibody that is humanized or partially humanized variant of SEQ ID NO. 1, wherein the VHH antibody comprises 2-13 substitutions selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, Y112X wherein X is selected from Y, H, V, E, S, and T, LI 15Q, and QI 18L to SEQ ID NO. 1, wherein the VHH antibody binds to human IL-17A, human IL-17F and / or human IL-17AF and inhibits IL- 17 receptor activation.
[0025] According to some embodiments, the humanized or partially humanized VHH antibody variant has at least 89% identity to SEQ ID NO. 1, wherein the VHH antibody comprises 2-13 substitutions selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, LI 15Q, and QI 18L to SEQ ID NO. 1, wherein position 112 is selected from Y, H, V, E, S, and T, and wherein the VHH antibody binds to human IL-17A and human IL-17F, and inhibits IL- 17 receptor activation.
[0026] According to some embodiments, the humanized or partially humanized VHH antibody comprises an amino acid sequence selected from SEQ ID NOs. 2-13, or a variant thereof having at least 95% identity with any of these sequences, wherein positions 62 and 63 of the VHH polypeptide are D (aspartic acid, Asp) and S (serine, S), respectively.
[0027] According to other embodiments, the humanized VHH antibody comprises an amino acid sequence selected from SEQ ID NOs. 2-13, or a variant thereof having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with any of these sequences.
[0028] According to some embodiments, the variant comprises a sequence having at least 98% or at least 99% to any of SEQ ID NOs. 2-13.
[0029] According to some embodiments, the invention provides a humanized VHH antibody that binds to and neutralizes IL-17A and IL-17F, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 2-13. Each possibility represents a separate embodiment of the invention.According to some embodiments, a variant of a humanized VHH antibody described above, comprises one amino acid residue that is substituted, deleted, or added. The substitutions may be selected from conservative substitutions, non-conservative substitutions, and combinations thereof. According to some specific embodiments, the substitution, deletion, or addition retains or improves at least one physical property of the humanized VHH antibody. According to some embodiments, a substitution improves the stability and / or producibility of a specific humanized VHH antibody according to the present invention or decreases the immunogenicity of the original sequence.
[0030] According to some embodiments, the humanized VHH antibody consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 2-13. Each possibility represents a separate embodiment of the invention.
[0031] The present invention provides, according to some embodiments, a humanized VHH antibody that binds to and neutralizes the binding of a human IL-17A and IL-17F to a human IL- 17 receptor; the humanized VHH antibody comprises the CDR3 sequence NDMPYGLDTRMDEYEXW (SEQ ID NO. 22) wherein X is selected from Y, H, V, E, S, and T.
[0032] According to some embodiments, the humanized VHH antibody that recognizes and neutralizes IL-17 comprises a set of 3 CDR sequences, wherein CDR1 comprises a sequence selected from SEQ ID NO. 14 and SEQ ID NO. 23, CDR2 comprises SEQ ID NO. 15, and CDR3 comprises a sequence selected from SEQ ID NOs. 16-21.
[0033] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 16.
[0034] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 17.
[0035] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 23, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 17.
[0036] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 18.
[0037] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 19.According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 20.
[0038] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 14, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 21.
[0039] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 23, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 20.
[0040] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 23, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 21.
[0041] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 23, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 18.
[0042] According to some particular embodiments, the humanized VHH antibody comprises CDR1 of SEQ ID NO. 23, CDR2 of SEQ ID NO. 15 and CDR3 comprises SEQ ID NO. 19.According to some embodiments, the humanized VHH antibody comprises at least two substitutions selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, Y112X, L115Q, QI 18L to SEQ ID NO. 1 (Re42B04), wherein X is any amino acid.
[0043] According to some embodiments, the humanized or partially humanized VHH antibody comprises the substitutions H62D and F63S to SEQ ID NO. 1 (RE42B04).
[0044] According to some embodiments, the humanized or partially humanized VHH antibody further comprises at least one substitution to SEQ ID NO. 1, the substitution is selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, L115Q, Q118L and a substitution of Y112 withH, V, E, S, or T.
[0045] According to some embodiments, the humanized or partially humanized VHH antibody is a variant of SEQ ID NO. 1 wherein position 1 is Q or E, position 14 is V or P, position 23 is E or A, position 62 is D, position 63 is S, position 75 is A or S, position 80 is H or Y, position 84 is D or N, position 87 is K or R, position 88 is P or A, position 112 is selected from Y, H, V, E, S, and T, position 115 is Q, and position 118 is Q or L.According to some embodiments, any of the amino acids at positions 24, 27, 28, 29, 35, 37, 44, 45, 47, 49, 53, 54, 57, 58, 59, 79 and 97 of the reference alpaca’s VHH antibody Re42B04 (SEQ ID NO. 1) are not mutated and are V24, L27, P28, V29, G35, F37, E44, R45, F47, A49, W53, 154, D57, S58, R59, V79, and N97 in the humanized or partially humanized VHH antibody of the present invention.
[0046] According to particular embodiments, the present invention provides the partially humanized VHH antibody Re42B04Human0 comprising a VHH sequence as shown in SEQ ID NO. 2, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0047] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Humanl comprising a VHH sequence as shown in SEQ ID NO. 3, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0048] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human2 comprising a VHH sequence as shown in SEQ ID NO. 4, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0049] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human3 comprising a VHH sequence as shown in SEQ ID NO. 5, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0050] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human4 comprising a VHH sequence as shown in SEQ ID NO. 6, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0051] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human5 comprising a VHH sequence as shown in SEQ ID NO. 7, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0052] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human6 comprising a VHH sequence as shown in SEQ ID NO. 8, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0053] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human7 comprising a VHH sequence as shown in SEQ ID NO. 9, or a VHH antibody, which is a variant thereof having at least 99% identity.According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human8 comprising a VHH sequence as shown in SEQ ID NO. 10, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0054] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Human9 comprising a VHH sequence as shown in SEQ ID NO. 11, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0055] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Humanl0 comprising a VHH sequence as shown in SEQ ID NO. 12, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0056] According to particular embodiments, the present invention provides the humanized VHH antibody Re42B04Humanl 1 comprising a VHH sequence as shown in SEQ ID NO. 13, or a VHH antibody, which is a variant thereof having at least 99% identity.
[0057] In certain embodiments, the humanized or partially humanized VHH antibody as described above is covalently or non-covalently conjugated to a heterologous moiety, which may be selected from a labeling group, a capture group, a half-life extension moiety, a multimerization moiety, or an effector group. The heterologous moiety may be connected directly or through a linker or a spacer.
[0058] In certain embodiments, the humanized or partially humanized VHH antibody as described above is fused to a heterologous polypeptide moiety, e.g., to an IgG Fc fragment, to serum albumin or to an albumin-binding moiety. In certain embodiments, the humanized VHH antibody is conjugated to one or several polymer moieties, particularly hydrophilic polymer moieties, such as polyethylene glycol (PEG), to increase the molecular weight of the antibody conjugate and, thus, delay renal clearance. The molecular weight of a polymer moiety may vary over a broad range, for example in the range of about 5 kDa to about 80 kDa. Such coupling may be performed through e.g., amino groups already present in the VHHs (e.g., amino terminals and / or side chains of lysine residues), or through engineered backbone or side chains of other amino acids, and involve known chemistries for forming amide bonds, secondary amine bonds, urea bonds or thioether bonds.According to some embodiments, the humanized VHH antibody neutralizes the binding of a human IL- 17 dimer to a human IL- 17 receptor. According to specific embodiments, the humanized VHH antibody neutralizes the binding of (i) a human IL-17A homodimer, (ii) a human IL-17F homodimer, and (iii) a human IL-17AF heterodimer to a human IL- 17 receptor. According to more specific embodiments, the humanized VHH antibody neutralizes the binding of at least one of (i) a human IL-17A homodimer, (ii) a human IL-17F homodimer, and (iii) a human IL-17AF heterodimer to a human IL-17 receptor at a concentration of about 10 nM or less, of about 3 nM or less, of about 1 nM or less, of about 0.3 nM or less, when tested in a cellbased assay under affinity-limited test conditions.
[0059] A humanized VHH antibody that is a variant having at least 99% sequence identity to the humanized VHH antibodies disclosed above and competes for IL-17 binding with any of the VHH antibodies disclosed above is also within the scope of the present invention.
[0060] According to some embodiments, the humanized VHH antibody is stable, particularly thermostable or hyperthermostable. According to some specific embodiments, the VHH antibody, in a disulfide bonded form, has a melting temperature of at least about 65°C, of at least about 80°C, of at least 90°C or of at least about 95°C when measured in disulfide-bonded form and under non-reducing conditions.
[0061] The humanized or partially humanized VHH antibody of any one of the previous embodiments, which is non-glycosylated or which is glycosylated.
[0062] According to some embodiments, the humanized or partially humanized VHH antibody or variant thereof is in a monovalent format.
[0063] According to some embodiments, the humanized or partially humanized VHH antibody or variant thereof is in a dimeric or multimeric format.
[0064] A humanized or partially humanized VHH antibody described above is suitable for use in medicine, e.g., human medicine, particularly for use in therapy, e.g., in the prevention or treatment of a disorder caused by and / or associated with an overactivity of IL- 17, particularly an overactivity of IL-17A and / or IL-17F.The present invention also provides, according to another aspect, a nucleic acid molecule encoding a humanized or partially humanized VHH antibody or a subunit of a VHH antibody described above, preferably in operative linkage with a heterologous expression control sequence, or included in a vector. According to some embodiments, the nucleic acid molecule is a DNA molecule. According to other embodiments, the nucleic acid molecule is an RNA molecule. The present invention also provides a recombinant cell or non-human organism transformed or transfected with a nucleic acid molecule or a vector.
[0065] According to some embodiments, the cell or organism is selected from a bacterium such as E. coli Bacillus sp., a unicellular eukaryotic organism, e.g., yeast such as Pichia pasloris. or I.eishmania. an insect cell, a mammalian cell, and a plant cell.
[0066] The invention also provides a method for recombinant production of a humanized or partially humanized VHH antibody described above, comprising cultivating a cell or an organism in a suitable medium and obtaining the humanized VHH antibody from the cell or organism or from the medium.
[0067] According to some embodiments, the method comprises cultivating cells selected from a bacterium, a yeast, an insect, a mammalian, and a plant. Each possibility represents a separate embodiment of the invention. According to some embodiments, the cells are mammalian cells. According to some embodiments, the mammalian cells are Chinese Hamster Ovary (CHO) cells. According to other embodiments, the method comprises cultivating yeast cells such as Pichia pastoris cells and obtaining the VHH antibody from the medium.
[0068] The invention further provides, according to another aspect, a pharmaceutical composition comprising at least one humanized or partially humanized VHH antibody defined above, and a pharmaceutically acceptable salt, excipient, or diluent.
[0069] According to some embodiments, the pharmaceutical composition comprises at least one humanized VHH antibody defined above, and a pharmaceutically acceptable salt, excipient, or diluent
[0070] According to some embodiments, the pharmaceutical composition comprises a plurality of humanized VHH antibodies described above, e.g., two or more different humanized or partially humanized VHH antibodies.According to some embodiments, the pharmaceutical composition is formulated for local administration. According to some embodiments, the pharmaceutical composition is formulated for topical administration. Pharmaceutical compositions provided according to the present invention may be formulated as liquid, solid or semi-solid states. According to some embodiments, the pharmaceutical composition is formulated as a cream, paste, gel, hydrogel, ointment, lotion, and emulsion. According to other embodiments, the pharmaceutical composition is a liquid formulation. According to some embodiments, the pharmaceutical composition is formulated for parenteral administration, e.g., by injection or infusion. According to some embodiments, the pharmaceutical composition is formulated for intradermal injection. According to some embodiments, the pharmaceutical composition is formulated as sustained release, slow release, or delayed release. According to some embodiments, the sustained release formulation comprises nanoparticles (e.g., lipid nanoparticles), PEG, micelles, or emulsions. According to some specific embodiments, the formulation is a liposomal or a lipid-based formulation.
[0071] According to some embodiments, the pharmaceutical composition is for use in the prevention or treatment of a disease or disorder caused by and / or associated with an overactivity of IL-17, particularly with an overactivity of IL-17A and / or IL-17F.
[0072] According to some embodiments, the pharmaceutical composition is for use in the prevention or treatment of an inflammatory and / or immune-related disease or disorder, or an infectious disease. According to some embodiments, the pharmaceutical composition is for use in the prevention or treatment of an inflammatory and / or immune-related skin disease or disorder.
[0073] According to some embodiments, the pharmaceutical composition is for use in the prevention or treatment of a disease, or combination of diseases selected from asthma, psoriasis, arthritis, hidradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, graft versus host disease, Alzheimer’s disease, fatty liver disease, sepsis, ischemic stroke, Parkinson’s disease, active non-radiographic axial spondylarthritis with objective clinical signs of inflammation, systemic lupus erythematosus (SLE), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hidradenitis suppurative (HS), pemphigus vulgaris (PV), pityriasis rubra pilaris (PRP), alopecia areata, systemic sclerosis, lichen planus, and impetigo herpetiformis.According to some embodiments, the psoriasis is selected from plaque psoriasis, moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, and pustular psoriasis.
[0074] According to some embodiments, the arthritis is selected from rheumatoid arthritis, psoriatic arthritis, and enthesitis-related arthritis.
[0075] According to some embodiments, the infectious disease is a viral, bacterial, or fungal disease. According to some embodiments, the viral infectious disease is caused by influenza virus infection or SARS-CoV-2 infection (COVID-19).
[0076] According to some embodiments the disease or disorder is psoriasis or arthritis.
[0077] According to some specific embodiments, the disease or disorder is selected from moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, generalized pustular psoriasis, Psoriatic arthritis, enthesitis-related arthritis, active non-radiographic axial spondylarthritis with objective clinical signs of inflammation, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), familial mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
[0078] According to some embodiments, psoriasis is plaque psoriasis. According to more specific embodiments the pharmaceutical composition is for use in prevention or treatment of mild to moderate plaque psoriasis.
[0079] A further aspect of the invention relates to a method for the prevention or treatment of a disease or disorder caused by and / or associated with an overactivity of IL-17, particularly an overactivity of IL-17A and / or IL-17F, comprising administering an effective dose of the humanized or partially humanized VHH antibody as described above or a pharmaceutical composition described above, to a subject in need thereof.
[0080] According to some embodiments, the subject is a human subject suffering from a disease or disorder caused by and / or associated with IL- 17, particularly associated with an overactivity of IL-17A and / or IL-17F.
[0081] According to some embodiments, the disease or disorder is an inflammatory or an immune disorder, or an infectious disease.According to some embodiments, the pharmaceutical composition is for use in the prevention or treatment of asthma, psoriasis, arthritis, hidradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, graft versus host disease, Alzheimer’s disease, fatty liver disease, sepsis, ischemic stroke, Parkinson’s disease, active non-radiographic axial spondylarthritis with objective clinical signs of inflammation, systemic lupus erythematosus (SLE), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hidradenitis suppurative (HS), pemphigus vulgaris (PV), pityriasis rubra pilaris (PRP), alopecia areata, systemic sclerosis, and infectious disease, lichen planus, and impetigo herpetiformis.
[0082] According to some embodiments, the psoriasis is selected from plaque psoriasis, moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, and pustular psoriasis.
[0083] According to some embodiments, the arthritis is selected from rheumatoid arthritis, psoriatic arthritis, and enthesitis-related arthritis.
[0084] According to some embodiments, the infectious disease is a viral, bacterial, or fungal disease. According to some embodiments, the infectious viral disease is caused by influenza virus infection or SARS-CoV-2 infection (COVID-19).
[0085] According to some specific embodiments, the disease or disorder is selected from moderate to severe plaque psoriasis, hypertrophic palmoplantar psoriasis, generalized pustular psoriasis, psoriatic arthritis, enthesitis-related arthritis, active non-radiographic axial spondylarthritis with objective clinical signs of inflammation, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), familial mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
[0086] According to some embodiments the disease or disorder is psoriasis or arthritis.
[0087] According to some embodiments, the disorder is psoriasis. According to more specific embodiments, the psoriasis is plaque psoriasis. According to yet more specific embodiments the disorder is mild to moderate plaque psoriasis.
[0088] According to some embodiments, the composition is administered parentally.
[0089] According to some embodiments, the administration is by injection. According to a specific embodiment, the administration is by intradermal injection.According to some embodiments, the composition is administered locally.
[0090] According to some embodiments, the composition is administered topically.
[0091] The present invention is explained in more detail by the following Figures and Examples.
[0092] BRIEF DESCRIPTION OF THE FIGURES
[0093] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
[0094] Figure 1: Sequences of selected humanized anti-IL-17 VHH antibodies.
[0095] The figure shows an alignment of sequences from humanized VHH antibodies derived from the alpaca’s VHH antibody Re42B04. Residues that deviate from the closest human germline variable heavy chain sequence, HV323 (UniProt No. P01764), are highlighted by gray background. The three CDR regions are indicated. An asterisk indicates a humanized residue, while a circle indicates a residue that was not humanized because it is buried and thus not solvent-exposed in the VHH-IL-17 complex. This information was derived from the determining an experimental structure of an VHH-IL-17 complex and further in silica model -building. CDR regions were also excluded from humanization. Likewise, the GLEW motif of the HV323 was not introduced, because it corresponds to the light chain-binding site of a human heavy chain. This motif is buried by the light chain. When introduced in the humanized Re42B04 variant, the GLEW motif would be a solvent-exposed neo-epitope and make the VHH unnecessary hydrophobic.
[0096] Figures 2A-2M: Affinities of humanized VHHs for IL-17A as measured by Bio-layer interferometry (BLI).
[0097] Graphs show binding of indicated concentrations of Re42B04-derived humanized VHH antibodies (as analytes) to biotinylated IL-17A that had been immobilized to High Precision Streptavidin biosensors. Binding and dissociation were recorded as wavelength shifts (in nm) on an Octet RED96e instrument (ForteBio / Sartorius). Baselines were recorded by measuring a ‘minus VHH control’ in parallel. On-rates, off-rates, and apparent dissociation constants (KDS)were calculated by the Octet Data Analysis HT 12.0 software), using a mass transport model to fit the data.
[0098] Figures 3A-3M: Affinities of humanized VHHs for IL-17F as measured by Bio-layer interferometry (BLI).
[0099] Measurements were as in Figure 2, the difference being that IL-17F had been immobilized to the sensors.
[0100] Figures 4A-4M: Thermal stability of disclosed VHH antibodies.
[0101] VHH antibodies (same as in Figure 2) were subjected to differential scanning fluorescence (DSF) as detailed in Example 3. Thermal unfolding during a stepwise increase in temperature is measured here as the enhanced fluorescence of added SYBR Orange with 532 nm excitation and a 555 nm long pass filter. The melting temperature (Tm) is defined as the inflection point of the first melting peak. For each VHH, the measurements were performed twice, first, for the VHH in its reduced state (indicated by “-SH HS-“), and second, after formation of the structural disulfide bond (indicated by “-S-S-“).
[0102] Figures 5A-5F: Dose-response of HEK-Blue™ IL-17 reporter cells to recombinant IL-17 cytokines.
[0103] Cells of the HEK-Blue™ IL- 17 reporter line were stimulated with increasing concentrations of human IL- 17 A, IL-17F, or IL-17AF. Stimulation results in the secretion of an embryonic alkaline phosphatase (SEAP) reporter, whose activity was determined colorimetrically using QUANTI-Blue™ as a substrate and measuring the resulting absorbance at 620 nm. The OD620 values, for stimulation with IL-17A are plotted in Figure 5A. The plots in Figure 5B depict the range of induction as calculated by dividing the OD620 readings at the respective IL-17A dilution by the OD620 value of the minus IL-17A control. Figures 5C and 5D similarly show the OD620 and the range of induction in response to IL-17F, while Figures 5E and 5F show the results for stimulation with IL-17AF. The results are the mean ± SD of one experiment measured intriplicate. Dashed vertical lines indicate the IL-17 concentrations that were used in the subsequent VHH neutralization experiments.
[0104] Figures 6A-6L: Neutralization of IL-17A and IL-17F by humanized VHH antibodies. Plots show the expression of a phosphatase reporter by HEK-Blue™ IL-17 cells, following induction by 0.17 nM IL-17A (Figures 6A-6D), 0.85 nM IL-17F (Figures 6E-6H) homodimers, or 0.85 nM IL17AF heterodimer (Figures 6i-6L) that had been pre-incubated with indicated concentrations, in nM (except for Figures 6B, 6F, and 6J in ng / ml), of anti-IL-17 VHH antibodies. In Figures 6B, 6F and 6 J, sonelokimab, a trimer of nanobodies targeting IL- 17 A, IL-17F, and albumin was included for comparison. A number of 1.0 indicates (full) induction in the absence of a VHH, and a number of 0 indicates no induction above the background of the minus IL- 17 controls.
[0105] DETAILED DESCRIPTION OF THE INVENTION
[0106] The present invention relates to humanized and partially humanized VHH antibodies that target and block human IL-17A and IL-17F.
[0107] The starting point for humanization was Re42B04 (having a sequence set forth in SEQ ID NO.
[0108] 1). The optimal solution to the humanization problem is to make the VHH as similar as possible to a human germ line variable heavy chain sequence, while preserving or even improving target binding, aggregation resistance, and thermostability. Finding such optimal solution from the VHH sequence alone was challenging because the VHH showed 37 deviations from the closest human germline sequence. Each mutation can have detrimental effects, and thus a very large number of combinations would need to be tested by trial and error (all possible combinations amount to 237~ 1011). Predictions of VHH-target interactions and even of details of the VHH fold by artificial intelligence methods, such as AlphaFold, are notoriously unreliable because the immune system “invents” truly new interactions, which then are missing in the training sets used for establishing the algorithm.To close this knowledge gap, the inventors determined an experimental structure of one Re42B04 class member bound to IL-17F and used this structure as a template for building models of the Re42B04 IL-17A and Re42B04 IL-17F structures. These models, in turn, revealed which VHH residues are solvent-accessible in these complexes and thus “allowed” to be changed during humanization. Furthermore, the models allowed to test in silico the consequences of individual and combined mutations. Most of the finally chosen mutations are neutral in respect to the biophysical properties of the VHH and the affinity to their targets. There are, however, three mutations, namely H62D, F63S, and LI 15Q (to SEQ ID NO. 1), that improve the thermostability up to the point of hyperthermostability. Furthermore, position Y112 was special, because this residue was not resolved in the crystal structure, which indicates flexibility. Therefore, several substitutions were tested at this position. All disclosed humanized variants show hyperthermostability (Figures 4A-4M), all of them bind IL-17A with picomolar affinity (Figures 2A-2M), bind IL-17F with 1 to sub-nM affinity (Figures 3A-3M). In cell-based assays, they neutralize IL-17A with a sub-nanomolar IC90 (Figures 6A-6D), IL-17F at a low nanomolar concentration (Figure 6E-6H), and IL-17AF with low nanomolar to sub-nanomolar IC90 (Figures 6i-6L) - without the need of exploiting avidity effects for targeting the IL- 17 dimers, as implemented with sonelokimab (a fusion with two different anti-IL-17 VHHs). Furthermore, all humanized Re42B04 variants neutralize IL-17A at a lower mass concentration than sonelokimab (Figures 6B, 6F, and 6J).
[0109] VHH antibodies
[0110] The sequences of the CDRs of humanized and partially humanized VHH antibodies of the present invention are listed in the following Table 1 while Table 2 lists the sequences of the full-length sequences of the humanized VHH antibodies.Table 1. CDR sequences of humanized anti-IL-17 VHH antibodies.
[0111] VHH SEQ CDR1 SEQ CDR2 SEQ CDR3 SEQ Re42B04 1 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEYW 16 HumanO 2 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEYW 16 Human 1 3 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEYW 16 Human2 4 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEHW 17 Human3 5 AVSGLPVSSYA 23 AISWIGGDSR 15 NDMPYGLDTRMDEYEHW 17 Human4 6 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEYW 18 Human5 7 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEEW 19 Human6 8 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYESW 20 Human? 9 EVSGLPVSSYA 14 AISWIGGDSR 15 NDMPYGLDTRMDEYEEW 21 Human8 10 AVSGLPVSSYA 23 AISWIGGDSR 15 NDMPYGLDTRMDEYESW 20 Human9 11 AVSGLPVSSYA 23 AISWIGGDSR 15 NDMPYGLDTRMDEYEEW 21 Human 10 12 AVSGLPVSSYA 23 AISWIGGDSR 15 NDMPYGLDTRMDEYEYW 18 Human 11 13 AVSGLPVSSYA 23 AISWIGGDSR 15 NDMPYGLDTRMDEYEEW 19
[0112]
[0113] Table 2. Sequences of humanized VHH antibodies
[0114] Name Amino acid sequence SEQ Re42B04 QVQLVESGGGLVQVGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYAHF 1
[0115] VKGRFTISRDNAKNTVHLQMDSLKPEDTAVYYCNDMPYGLDTRMDEYEYWGLGTQVTVSS
[0116] Re42B04 QVQLVESGGGLVQVGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 2 HumanO VKGRFTISRDNAKNTVHLQMDSLKPEDTAVYYCNDMPYGLDTRMDEYEYWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 3 Human 1 VKGRFTISRDNSKNTVHLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYEYWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 4 Human2 VKGRFTISRDNSKNTVYLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYEHWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCAVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 5 Human3 VKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCNDMPYGLDTRMDEYEHWGQGTLVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 6 Human4 VKGRFTISRDNSKNTVYLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYEVWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 7 Human5 VKGRFTISRDNSKNTVYLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYEEWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 8 Human6 VKGRFTISRDNSKNTVYLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYESWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCEVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 9 Human? VKGRFTISRDNSKNTVYLQMDSLRAEDTAVYYCNDMPYGLDTRMDEYETWGQGTQVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCAVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 10 Human8 VKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCNDMPYGLDTRMDEYESWGQGTLVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCAVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 11 Human9 VKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCNDMPYGLDTRMDEYETWGQGTLVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCAVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 12 Human 10 VKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCNDMPYGLDTRMDEYEVWGQGTLVTVSS Re42B04 EVQLVESGGGLVQPGGSLRLSCAVSGLPVSSYAMGWFRQAPEKEREFVAAISWIGGDSRYADS 13
[0117]
[0118] Human 11 VKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCNDMPYGLDTRMDEYEEWGQGTLVTVSSA non-limitative list of humanized VHH antibodies of the present invention and their stability and affinities to IL-17A and IL-17F, compared to their alpaca’s reference VHH antibody, is shown below in Table 3.
[0119] According to the present invention a partially humanized VHH antibody is a variant of SEQ ID NO. 1 wherein position 1 is Q or E, position 14 is V or P, position 23 is E or A, position 62 is D, position 63 is S, position 75 is A or S, position 80 is H or Y, position 84 is D or N, position 87 is K or R, position 88 is P or A, position 112 is selected from Y, H, V, E, S, and T, position 115 is Q, and position 118 is Q or L. A humanized VHH antibody according to the present invention comprises an amino acid sequence selected from SEQ ID NOs. 2-13, or a variant thereof having at least 95% identity with any of these sequences, excluding the sequence set forth as SEQ ID NO. 1. According to some embodiments, the humanized VHH antibody is a variant having at least 95% identity to any of SEQ ID Nos. 2-13, wherein positions 62 and 63 are DS.
[0120] The affinities of the humanized VHH antibody to the IL- 17 paralogs may be measured using methods known in the art. Particular measurement methods use biolayer interferometry (BLI) instruments. IL-17 is immobilized on the chip and binding of monomeric VHH antibodies is measured. According to particular embodiments, the binding affinity of a monomeric VHH, expressed as a dissociation constant KD, to an immobilized human IL-17A or IL-17F homodimer is determined.
[0121] Table 3: Humanized anti-IL-17 VHH antibodies and their properties
[0122] VHH SEQ ID Tm Tm KDKD
[0123] No. (reduced) disulfide IL-17A IL-17F
[0124] Re42B04 1 40°C 59°C 60 pM 380 pM Re42B04human0 2 49°C >95°C 160 pM 830 pM
[0125] Human 1 3 46°C >95°C 210 pM 660 pM
[0126] Human2 4 50°C >95°C 250 pM 900 pM
[0127] Human3 5 50°C >95°C 250 pM 1200 pM
[0128] Human4 6 48°C >95°C 160 pM 580 pM
[0129] Human5 7 46°C >95°C 120 pM 560 pM
[0130] Human6 8 48°C >95°C 140 pM 670 pM
[0131] Human7 9 48°C >95°C 190 pM 370 pM
[0132] Human8 10 47°C >95°C 180 pM 290 pM
[0133] Human9 11 47°C >95°C 190 pM 500pM
[0134] Human 10 12 47°C >95°C 140 pM 680 pM
[0135]
[0136] Human 11 13 46°C >95°C 170 pM 1100 pMThe present invention relates to a humanized VHH antibody, which is a monovalent heavy chain-only antibody comprising a CDR1 domain, a CDR2 domain and a CDR3 domain linked by humanized framework regions including, humanized VHH antibody fragments and humanized VHH antibody fusion proteins, e.g. a fusion protein with an immunoglobulin or nonimmunoglobulin peptide or polypeptide, as long as it shows the properties according to the invention.
[0137] There are several methods known in the art for determining the CDR sequences of a given antibody molecule, but there is no standard unequivocal method. Determination of CDR sequences from antibody heavy chain variable regions can be made according to any method known in the art, including, but not limited to, the methods known as KABAT, Chothia, and IMGT. Common determination methods like KABAT would exclude essential parts of the variable regions as a VHH antibody binding site (paratope) often includes residues of the scaffold and outside a narrowly defined CDR region. This is also a difference between nanobodies and traditional antibodies. Other methods of identifying a binding site and CDR sequences of VHH antibodies include the use of custom reference databases utilizing large collection of VHH antibody sequencing data. A selected set of CDRs may include sequences identified by more than one method. CDRs may also be defined through a multiple alignment (with many other VHH antibodies), to identify the hot-spots of variability and relate them to a standard VHH antibody structure. It is also possible to define CDRs by analyzing the structure of the VHH antibody and deciding what is a loop and what is the antibody’s scaffold. In some cases, CDR-adjacent residues are also variable, and are therefore included in the CDR definition. According to some embodiments of the present invention, the CDR sequences of the humanized VHH antibodies variable regions are determined using custom reference database, containing sequencing data of >10000 VHH antibodies.
[0138] The present invention is also directed to a covalent or non-covalent conjugate of a humanized VHH antibody molecule to a non-proteinaceous structure, for example, a labeling group, a capture group such a solid phase-binding group, or an effector group such as a toxin. For example, the heterologous moiety may be from a fluorescence group, biotin, an enzyme such as a peroxidase, phosphatase, or luciferase, a hapten, an affinity tag, or a nucleic acid such as an oligonucleotide.The humanized VHH antibody of the present invention is particularly a monoclonal VHH antibody characterized by a specific amino acid sequence. The humanized VHH antibody may be produced in a prokaryotic host cell, a yeast cell or a mammalian cell. In certain embodiments, the humanized VHH antibody is non-glycosylated.
[0139] In certain embodiments, the humanized VHH antibody is glycosylated, wherein a carbohydrate structure may be derived from a glycosylation site introduced into the humanized VHH sequence and / or from a fusion partner.
[0140] A humanized VHH antibody according to the present invention is characterized by (i) a CDR3 sequence, (ii) a combination of a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence, (iii) by a complete VHH sequence, or (iv) by specific substitutions to amino acid residues in a specific reference antibody. Specific CDR and VHH sequences are provided in the Tables, Figures and the Sequence Listing.
[0141] According to the present invention, sequences related to the above sequences, namely variants or analogs, are encompassed. These related sequences are defined by having a minimum identity to a specifically indicated amino acid sequence, e.g., a CDR or VHH sequence. This identity is indicated over the whole length of the respective reference sequence and may be determined by using well-known algorithms such as BLAST.
[0142] In particular embodiments, a related CDR3 sequence of a humanized VHH antibody comprises a substitution of one amino acid, in particular of SEQ ID NO. 1.
[0143] In particular embodiments, a related humanized VHH sequence has an identity of 99% to a VHH sequence, e.g., comprises a substitution of one amino acid, preferably a non-CDR amino acid, wherein the substitution does not destroy the affinity, activity, stability or reproducibility of the humanized VHH antibody and does not increase its immunogenicity.
[0144] Further, the invention refers to a humanized VHH antibody, which competes with a specific humanized VHH antibody disclosed herein for the binding to a human IL-17 polypeptide. In certain embodiments, a competing humanized VHH antibody binds the same or an overlapping epitope on the human IL-17 polypeptide. For example, the invention refers to a VHH antibody, which competes with any of VHH antibodies Re42B04Human0-ll (SEQ ID NOs. 2-13). Competition may be determined by label-free biolayer interferometry performed as a crosscompetition or epitope binning assay using a label-free detection system, e.g., an Octet® system from Sartorius, according to the manufacturer's instructions.In particular embodiments, one amino acid of a reference sequence, including an amino acid in a CDR1, CDR2 or CDR3 sequence and / or an amino acid in a framework region, is replaced by another amino acid, while preserving structural integrity and epitope-binding of the VHH antibody. These exchanges can be conservative (i.e., by a similar amino acid) or nonconservative.
[0145] In further particular embodiments, one amino acid of a reference sequence, including an amino acid in a CDR1, CDR2 or CDR3 sequence and / or an amino acid in a framework region, is replaced by a conservative amino acid substitution, i.e. a substitution of an amino acid by another amino acid with similar biochemical properties, for example a substitution of an aliphatic amino acid, e.g. Gly, Ala, Vai, Leu, or He, for another aliphatic amino acid; a substitution of a basic amino acid, e.g., Lys or Arg, against another basic amino acid or against Met; a substitution of an acidic amino acid or an amide thereof, e.g., Asp, Glu, Asn or Gin, against another acidic amino acid or an amide thereof; a substitution of an aromatic amino acid, e.g., Phe, Tyr or Trp, against another aromatic amino acid.
[0146] Further, the present invention relates to a nucleic acid molecule, e.g., a DNA molecule, or an RNA molecule, encoding a VHH as indicated above, or a vector or construct, comprising said nucleic acid molecule as indicated above in operative linkage with an expression control sequence, particularly with a heterologous expression control sequence. Furthermore, the invention relates to a cell comprising a nucleic acid molecule or a vector as described above. Vectors for the recombinant production of VHH antibodies are well-known in the art. In certain embodiments, the vector is an extrachromosomal vector. In other embodiments, the vector is a vector for genomic integration. The cell may be a known host cell for producing antibodies or antibody fragments, e.g., a prokaryotic cell such as an E. coli or a Bacillus sp. cell, a yeast cell, particularly a Pichia yeast cell, an insect cell or a mammalian cell, e.g., a CHO cell, or a plant cell. In certain embodiments, the cell comprises the nucleic acid or the vector extrachromosomally. In other embodiments, the cell comprises the nucleic acid or the vector integrated into the genome, e.g., as a genomically integrated expression cassette.
[0147] Still a further aspect of the present invention is a method of recombinantly producing a VHH antibody by growing a cell as described above in a culture medium and obtaining the VHH antibody from the cell or the culture medium. Suitable culture media and culture conditions are well known in the art.Binding to human IL-17
[0148] The VHH antibodies of the present invention bind to a human IL- 17 polypeptide. The inventors have designed humanized VHH antibodies, which bind with high affinity to human IL- 17 polypeptides and cross-react with (i) a human IL-17A homodimer, (ii) and human IL-17F homodimer as shown in Table 3.
[0149] The human genome encodes six IL- 17 paralogs, IL-17A through IL-17F :
[0150] IL-17A (UniProt Accession No. QI 6552),
[0151] IL-17B (UniProt Accession No. Q9UHF),
[0152] IL-17C (UniProt Accession No. Q9P0M4),
[0153] IL-17D (UniProt Accession No. Q8TAD2),
[0154] IL-17E (UniProt Accession No. Q9H293),
[0155] IL-17F (UniProt Accession No. Q96PD4).
[0156] The VHH antibodies of the present invention bind at least to the following IL- 17 paralogs: “human IL- 17 A” (UniProt Accession No. QI 6552), particularly in the form of a homodimer comprising two IL-17A units; IL-17F (UniProt Accession No. Q96PD4) particularly in the form of a homodimer comprising two IL-17F units; and IL-17AF in the form of a heterodimer comprising one IL-17A unit and one IL-17F unit.
[0157] It should be noted, however, that the term “human IL-17” also encompasses naturally occurring variants of human IL- 17 polypeptides and genetically modified polypeptides as described herein. The inventors have performed their selection and binding experiments of the alpaca’s VHH antibodies with genetically modified IL-17A and IL-17F polypeptides as follows:
[0158] An IL-17A homodimer that comprises amino acid residues 40-155 of human IL- 17A (UniProt Q16552). This corresponds to the portion that is well-ordered in crystal structures. The first five amino acids (GSEDS) are spacer residues. Further, this sequence comprises two point mutations: N68D (eliminates an N-glycosylation site) and C192S (eliminates an unpaired cysteine that would otherwise cause problems in recombinant expression).
[0159] An IL-17F homodimer that comprises amino acid residues 39-163 of human IL- 17F (UniProt Q96PD4), with an N83D mutation to eliminate an N-glycosylation site. The first five residues (GSEGE) are a linker.The above bacterially expressed IL-17A and IL-17F proteins were used during the initial immunization, selection, characterization, and crystallization.
[0160] For immunization and selection of second generation VHH antibodies and for their characterization, mammalian expressed versions of IL-17A and IL-17F, which lack the indicated modification were used as follows:
[0161] Mature human IL-17A in mammalian expression (UniProt Q16552).
[0162] Mature human IL-17F in mammalian expression (UniProt Q96PD4).
[0163] In certain embodiments, the humanized VHH antibody of the present invention binds to a human IL-17A homodimer, and a human IL-17F homodimer wherein the binding affinity of a monomeric humanized VHH, expressed as dissociation constant KD to human IL-17A is 500 pM, 300 pM, 100 pM, 50 pM, 30 pM or less, and wherein the binding affinity of a monomeric humanized VHH, expressed as a dissociation constant KD, to IL-17F homodimer is 5 nM, 2 nM, 1 nM, 500 pM, 300 pM, 100 pM or less. The binding affinity may be determined as described herein in detail in the Examples and Figures, using e.g., the polypeptides described above.
[0164] IL- 17 neutralization
[0165] The humanized VHH antibodies of the present invention are capable of neutralizing the binding of human IL-17 dimer to a human IL-17 receptor and are capable of preventing or inhibiting activation of the receptor. The inventors have designed humanized VHH antibodies, which cross-neutralize (i) a human IL-17A homodimer, and (ii) a human IL-17F homodimer as shown in Table 3.
[0166] In certain embodiments, the humanized VHH antibody of the present invention cross-neutralizes the binding of a human IL- 17 polypeptide, particularly a human IL-17A homodimer, and a human IL-17F homodimer to a human IL- 17 receptor. The neutralization potency may be determined as described herein in detail in the Examples.
[0167] Stability
[0168] For the intended therapeutic application, the humanized anti-IL-17 VHH antibodies should not only be highly potent in interleukin neutralization, but also, they should be developable as biological drugs. This includes that they are stable enough to survive a lengthy, large-scale production process as well as transportation and storage (ideally for years in liquid, semi-liquid or solid formulations) without aggregation or loss of activity.A good predictor for stability is thermostability, which can be measured, e.g., by thermal shift assays or specifically by differential scanning fluorimetry. The present inventors have identified several thermostable or hyperthermostable VHH antibodies as shown in Table 3.
[0169] In a particular embodiment, the invention relates to a humanized VHH antibody, which is stable, particularly thermostable, or hyperthermostable. Preferably, the humanized VHH antibody has a melting point (melting temperature) of at least about 65°C, of at least about 80°C, of at least 90°C or of at least about 95°C, and / or an aggregation temperature of at least about 50°C, of at least about 60°C, of at least 70°C or of at least about 80°C when measured in disulfide-bonded form and under non-reducing conditions. Melting and aggregation temperatures are determined as described herein.
[0170] VHH antibodies are considered stable if the fluorescence intensity at the melting peak exceeds the initial fluorescence at 20°C by no more than 10%, the rational being that such small increase is inconsistent with a global melting of the VHH. For each VHH, the measurements were performed twice, first, for the VHH in its reduced state (indicated by “-SH HS-“), and second, after formation of the structural disulfide bond (indicated by “-S-S-“) as disclosed previously in WO2024 / 256467.
[0171] Melting is determined as described in Example 3. According to some embodiments, a stable humanized VHH antibody has a melting point (melting temperature) of at least about 65 °C, and an hyperthermostable humanized VHH antibody has a melting point (melting temperature) of at least 95°C, when measured under non-reducing conditions for a disulfide-bonded version. It should be noted however that the outcome of a stability measurement depends on the conditions. The stability is also influenced by the buffer composition and the additives used.
[0172] Monovalent and bivalent VHH antibodies
[0173] In certain embodiments, the humanized VHH antibody of the present invention is in a monovalent format, i.e., it has a single binding site for a human IL-17 polypeptide. In these embodiments, the humanized VHH antibody may be present as such or covalently or non-covalently attached to a heterologous moiety, e.g., a peptidic or non-peptidic moiety.
[0174] In further embodiments, the humanized VHH antibody of the present invention is in a multimeric, particularly a dimeric format. In these embodiments, two humanized VHH antibody units may be covalently or non-covalently attached to each other together via a linker and / or a dimerization moiety.In certain embodiments, the humanized VHH antibody is a homodimeric VHH antibody, wherein two humanized VHH antibodies are covalently attached via a dimerization moiety, e.g., an immunoglobulin Fc fragment.
[0175] In certain embodiments, the humanized VHH antibody is a heterodimeric VHH antibody, particularly a covalently linked humanized VHH heterodimer comprising a first humanized VHH antibody and a second humanized VHH antibody wherein the first and the second humanized VHH antibodies bind to different epitopes on IL- 17 or wherein the first humanized VHH antibody binds to IL- 17 and the second humanized VHH antibody binds to a different target.
[0176] Production of VHH antibodies
[0177] Humanized VHH antibodies including monomeric and dimeric forms may be produced, for example as described in WO 2022 / 023483 and WO 2022 / 023484, or by other methods well known in the art.
[0178] Humanized VHH antibodies may be produced using any method known in the art for producing proteins, antibodies and nanobodies. Typically, the humanized VHH antibodies are produced recombinantly in a prokaryotic or eukaryotic host cell system or host organism, such as a bacterium, a yeast, a plant cell or in a mammalian cell. For this purpose, a nucleic acid molecule encoding the humanized VHH antibody is introduced into the host cell or host organism and expressed in the host cell or host organism. The nucleic acid molecule may encode a monomeric humanized VHH antibody or a subunit of a dimeric humanized VHH antibody, or a multimeric construct comprising at least one VHH antibody herein disclosed.
[0179] In a particular embodiment, the humanized VHH antibody is recombinantly produced in a bacterium, e.g., E. coli or Bacillus. For example, expression in a bacterium may involve cytoplasmic, periplasmic or secretory expression followed by purification of the humanized VHH antibody from the host cell, or the culture medium. In certain embodiments, the nucleic acid sequence encoding the humanized VHH antibody is fused to at least one sequence directing the expression to the periplasm and / or into the culture medium.In a further particular embodiment, the humanized VHH antibody is recombinantly produced in a eukaryotic host cell or host organism, preferably in yeast, e.g., in Pichia pasloris. Saccharomyces cerevisiae. or Hansenula polymorpha, or in an animal cell, particularly in a mammalian cell, e.g., human or a hamster cell. In certain embodiments, the nucleic acid sequence encoding the humanized VHH antibody is fused to at least one sequence directing the expression into the culture medium.
[0180] Nucleic acid sequences
[0181] In some embodiments of the present invention, a recombinant nucleic acid sequence encoding a humanized VHH antibody specific to human IL- 17 is provided, wherein the nucleic acid sequence is operatively linked to at least one transcription control element to form a recombinant molecule, also referred to herein as a recombinant construct.
[0182] The nucleic acid sequence may include DNA, RNA, or their derivatives. An isolated nucleic acid sequence encoding a humanized VHH antibody specific to IL- 17 may be obtained from its natural source, either as an entire (i.e., complete) gene or a portion thereof. A nucleic acid molecule can also be produced using recombinant technology (employing well-known nucleic acid cloning techniques such as polymerase chain reaction (PCR) amplification) or chemical synthesis. Nucleic acid sequences include natural nucleic acid sequences and homologs thereof, including, but not limited to, natural allelic variants and modified nucleic acid sequences in which nucleotides have been inserted, deleted, substituted, and / or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecule's ability to encode a functional humanized VHH antibody that targets IL-17 or an active fragment or a conjugate thereof.
[0183] A nucleic acid sequence homolog can be purchased as a gene synthesis or produced using a number of methods known to those skilled in the art. For example, nucleic acid sequences can be modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, PCR amplification and / or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologues can be selected from a mixture of modified nucleic acids by screening for the function of the protein encoded by the nucleic acid.The phrase "operatively linked" refers to linking a nucleic acid sequence to a transcription control sequence in such a manner that the encoded protein molecule is able to be expressed when the nucleic acid sequence is transfected (i.e., transformed, transduced or transfected) into a host cell. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences.
[0184] Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Transcription control sequences include those which function in animal, bacteria, insect cells, and preferably in animal cells. Particular transcription control sequences include, but are not limited to RSV control sequences, CMV control sequences, retroviral LTR sequences, SV-40 control sequences and beta-actin control sequences as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and enhancers, and heat shock elements (HSEs).
[0185] It may be appreciated by one skilled in the art that use of recombinant DNA technologies can improve expression of transfected nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of secretion. Post-translational modifications, related to secretion, include cleavage of the signal peptide and formation of a disulfide bond. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals, modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, and deletion of sequences that destabilize transcripts, or operatively linking nucleic acid molecules to high-copy number plasmids in E. coli. In the case of mammalian expression, one would introduce an intron that enhances transcript stability and export from the cell nucleus.The DNA molecules of the present invention encode according to some embodiments, humanized antibodies that bind to and target human IL-17, or a conjugate thereof, wherein the VHH antibody or conjugate comprises a set of 3 CDR sequences. Representative sets of CDR sequences are presented in Table 2 while sequences of VHH antibodies encoded by the DNA molecules of the present invention are provided in Table 3.
[0186] DNA sequences encoding the humanized VHH antibodies may be obtained as cDNA sequences isolated from immunized alpaca, or they may be reverse translated from the amino acid sequences using computer programs known in the art. All optional encoding sequences are included within the scope of the present invention.
[0187] Therapeutic applications and methods of use
[0188] Still a further aspect of the present invention is the use of a humanized VHH antibody as described above in medicine, particularly for therapeutic use. In certain embodiments, the humanized VHH antibody is used in human medicine.
[0189] The humanized VHH antibody of the present invention is useful in the prevention or treatment of a disease or disorder caused by and / or associated with an overactivity of IL-17, particularly associated with an overactivity of IL-17A and / or IL-17F.
[0190] In certain embodiments, the humanized VHH antibody is useful in the prevention or treatment of an inflammatory, infectious and / or immune-related disease or disorder, e.g., an inflammatory and / or immune-related skin disorder.
[0191] Exemplary disorders are asthma, psoriasis, e.g., plaque psoriasis, arthritis, e.g., rheumatoid arthritis or psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, Graft versus Host Disease, Alzheimer’s disease, fatty liver disease, COVID-19, sepsis, ischemic stroke, Parkinson’s disease, influenza virus infection.
[0192] In some embodiments, the disorder is plaque psoriasis. In specific embodiments, the disorder is mild or moderate plaque psoriasis. In other specific embodiments, the disorder is severe plaque psoriasis.In therapeutic applications, the humanized VHH antibody is administered in an effective dose to a subject in need thereof, particularly to a human subject. The dose will depend on the specific type of agent, e.g., monovalent VHH antibody or dimeric VHH antibody, the type of disease, and the route of administration.
[0193] Typically, the humanized VHH antibody is administered as a pharmaceutical composition comprising the active agent and a pharmaceutically acceptable salt, diluent or excipient. Examples of suitable salts, diluents and excipients for formulating antibodies or antibody fragments are well-known in the art.
[0194] The present invention further provides methods of treating diseases and disorders associated with overexpression or overactivity of human IL- 17, comprising administering to a subject in need of such treatment a pharmaceutical composition comprising an effective dose of a humanized VHH antibody that neutralizes IL- 17 receptor activation, and a pharmaceutically acceptable salt, diluent or excipient, thereby treating the disease or disorder.
[0195] In certain embodiments, disease or disorder is an inflammatory and / or immune-related disorder, or an infectious disease. According to more particular embodiments, the disease or disorder is an inflammatory and / or immune-related skin disorder.
[0196] Exemplary disorders treatable with the humanized VHH antibodies of the present invention are psoriasis, e.g., plaque psoriasis, asthma, arthritis, e.g., rheumatoid arthritis or psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, Graft versus Host Disease, Alzheimer’s disease, fatty liver disease, COVID-19, sepsis, ischemic stroke, Parkinson’s disease, influenza virus infection.
[0197] In some embodiments, the disorder is plaque psoriasis. In specific embodiments, the disorder is mild or moderate plaque psoriasis.
[0198] According to some embodiments, the pharmaceutical composition comprising an effective dose of a humanized VHH antibody that neutralizes IL-17 is administered locally to a site of a subject in need of such treatment, and a pharmaceutically acceptable salt, diluent or excipient, thereby treating the disease or disorder.The terms “administering locally”, “local administration” or “dermal administration” mean that the humanized VHH antibody is not administered systematically. The terms include in particular topical application on the surface of the skin. Local administration also encompasses administration of the composition by injection, particularly by intraepidermal injection and / or intradermal (ID) injection and / or subdermal injection and / or subcutaneous (SC) injection and / or micro-injection.
[0199] The compositions of the present invention are suitable, according to some embodiments, for administration by topical or injectable routes of administration (in particular intraepidermal and / or intradermal and / or micro-injection, and / or by systemic injection, e.g., subcutaneous injection.
[0200] The methods of the present invention also include administering locally the pharmaceutical composition to a defined area of skin.
[0201] The treatment period is ideally of sufficient time to provide an improvement of the disease or disorder treated. The treatment period can be at least 1 week, and in some embodiments the treatment period can last about 4 weeks, 8 weeks, or 12 weeks. In certain embodiments, the treatment period will extend over multiple months (i.e., 3-12 months) or multiple years. In one embodiment, the pharmaceutical composition is applied at least once a day during a treatment period of at least 4 weeks, 8 weeks, or 12 weeks. In one embodiment, the pharmaceutical composition is applied twice a day during a treatment period of at least 4 weeks, 8 weeks, or 12 weeks. Alternatively, the pharmaceutical composition is administered once every other day, once every three days, once a week for a week, a month, or as long as an improvement is achieved. While the subject for the treatment methods may be of any suitable age, the subject is, in some embodiments, a child, an adult or a geriatric subject.
[0202] The pharmaceutical composition and methods suitable for dermal administration may be used in combination with mechanical devices, such as massage-roller devices having a mechanical and rubbing action to facilitate penetration of the active agent, or wave-emitting systems (light, infrared frequencies, etc.) which activate the response of the skin. Additional means that may be used or combined with the other administration routs are patches and microneedles.The pharmaceutical compositions and methods of the invention suitable for injection, in particular for intraepidermal and / or intradermal and / or subcutaneous injection and / or microinjection, can be injected by a device comprising a needle or microneedle or by a needle-free injection device. Such devices are well known in mesotherapy. Alternatively, the pharmaceutical compositions can be administered by means of iontophoresis directly to achieve a greater penetration of the active agent.
[0203] The terms "treat," "treating," and "treatment" may be used interchangeably and are all intended to refer to an amelioration or reversal of at least one measurable physical parameter related to the amendable disease or disorder, for example to inhibiting, preventing or arresting the development of a disease or disorder and / or causing the reduction, remission, or regression of a disease or disorder.
[0204] The phrase "inflammatory disease or disorder" used herein refers to a disease, condition or disorder associated with inflammation. The term "inflammation" as used herein refers to the process by which a subject's immune system coordinates a response to tissue damage, infection, antigenic challenge, etc. Inflammation may be associated with an increased blood supply to the tissue, increased capillary permeability in the tissue and / or increased leukocyte migration to the tissue.
[0205] According to some embodiments of the present invention, the inflammatory disease or disorder is an autoimmune disease or disorder. The autoimmune disease or disorder can be, but not limited to psoriasis, arthritis, systemic lupus erythematosus (Lupus, SLE), multiple sclerosis (MS), and inflammatory bowel disease (IBD).
[0206] The term “immune-related disease or disorder” encompasses any condition associated with disfunction, under reactivity or over reactivity of any component of the immune system. This term includes autoimmune diseases, inflammatory conditions as well as allergies, cytokine storm conditions and immune deficiencies. An immune related disease or disorder according to the present invention may be acquired and congenital.
[0207] The term “infectious disease” encompasses any disease, disorder or condition caused by a pathogen. The term includes viral, bacterial, fungal and parasite diseases and disorders.The term “skin disease or disorder” includes any abnormal condition, illness or damage to the skin, including to the epidermis, dermis, and hypodermis. A skin disease or disorder includes conditions caused by pathogens as well as allergic and other immune-related and auto-immune conditions.
[0208] Pharmaceutical compositions
[0209] The humanized VHH antibodies of the present invention may be formulated in pharmaceutical compositions according to the intended use.
[0210] The present invention provides pharmaceutical compositions comprising as an active agent at least one humanized VHH antibody that neutralize IL-17 and a pharmaceutically acceptable salt, diluent, or excipient.
[0211] The term “pharmaceutical composition” as used herein refers to a composition suitable for treating a disease or disorder, caused by and / or associated with an overactivity of IL- 17, particularly associated with an overactivity of IL-17A and / or IL-17F. Particularly, the pharmaceutical compositions are useful in the prevention or treatment of an inflammatory and / or immune-related disorder, e.g., an inflammatory and / or immune-related skin disorder. Exemplary disorders are asthma, psoriasis, e.g., plaque psoriasis, arthritis, e.g., rheumatoid arthritis or psoriatic arthritis, hi dradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, graft versus host Disease, Alzheimer’s disease, fatty liver disease, COVID-19, sepsis, ischemic stroke, Parkinson’s disease, influenza virus infection.
[0212] The pharmaceutical compositions further comprise a pharmaceutically acceptable salt, diluent or excipient.
[0213] According to some embodiments, the pharmaceutical composition further comprises one or more excipient, salt, or buffer. According to some embodiments, the pharmaceutical composition comprises an excipient selected from the group consisting of pH buffering agents, preservatives, chelating agents, tonicity agents, humectants, and antioxidants.
[0214] According to additional embodiments, the pharmaceutical composition is in the form selected from the group consisting of a solution, emulsion, nanoemulsion, suspension, lipid nanoparticles (e.g., liposomes), microparticles, ointment, cream, lotion, paste, gel, hydrogel, spray, powder, stick, and a patch. Each possibility represents a separate embodiment of the invention.The term “pharmaceutical acceptable” as used herein mean approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in humans. The constituents of the pharmaceutical compositions of the present invention are all pharmaceutically acceptable agents.
[0215] The composition, if desired, can also contain minor amounts of pH buffering agents such as acetates, citrates or phosphates. Preservatives such as benzyl alcohol or methyl parabens; chelating agents such as ethylenediaminetetraacetic acid; and agents for the adjustment of tonicity such as sodium chloride trehalose or sucrose, are also envisioned.
[0216] Other optional excipients include, but are not limited to, humectants such as water-soluble liquid polyols, e.g., glycerin, sorbitol, propylene glycol, antioxidants, and mixtures thereof.
[0217] Depot formulations of the VHH antibodies of the present invention are therefore included within its scope.
[0218] For injection, the pharmaceutical composition can be formulated as a liquid such as an aqueous solution. According to preferred embodiments, the pharmaceutical composition is a sterile solution. Acceptable solvents include, but are not limited to, water, Ringer's solution and isotonic sodium chloride.
[0219] In some embodiments, the active agent, with or without excipients, are maintained in a separate state from the excipient or solvent, for example, as a dry powder. The intermixing of the desired amount of the active agent with the desired amount of the excipient or solvent, performed by the subject immediately prior to application of the pharmaceutical composition, ensures that the active agent will retain its maximum efficacy, and will also permit the potency of the composition to be tailored to the individual needs of the subject. The resulting pharmaceutical composition may be then applied locally or systematically.
[0220] According to further embodiments, the pharmaceutical composition is administered locally. According to certain embodiments, the pharmaceutical composition is administered topically, said composition is in the form of an ointment, cream, lotion, paste, gel, hydrogel, spray, powder, stick, or a patch.
[0221] Depending on the stage and the severity of the disorder, the pharmaceutical composition may be administered once or several times during the course of the disorder. For example, it may be administered once or several times daily, each second day, two times weekly, weekly, monthly or every few months, for a suitable period of time.In certain embodiments, the pharmaceutical composition is administered parentally, e.g., by intravenous, subcutaneous, or intramuscular injection or by infusion. In certain embodiments, the pharmaceutical composition is administered by injection. According to certain embodiments, the pharmaceutical composition administered by injection or infusion is in the form of a solution. In further embodiments, the pharmaceutical composition is administered locally, e.g., topically, orally, nasally or intrapulmonary, for example by inhalation as an aerosol.
[0222] According to some embodiments, the humanized VHH antibodies are formulated for local or topical administration.
[0223] The humanized VHH antibody may be administered alone or together with a further active agent or treatment, particularly with a further agent that is useful in the prevention and / or treatment of a disorder caused by and / or associated with IL- 17 overactivity, particularly associated with an overactivity of IL-17A and / or IL-17F.
[0224] Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective dose means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disease or disorder of the subject being treated.
[0225] The term “effective dose” is that amount of the active agent which is sufficient to provide a beneficial effect to the subject to which the composition is administered.
[0226] Determination of a therapeutically effective dose is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0227] For any preparation used in the methods of the invention, the therapeutically effective dose or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in an animal model to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact, route of administration and dosage can be chosen by the individual physician in view of the patient's condition.
[0228] Dosage amount and interval may be adjusted individually to levels of the active ingredient which are sufficient to achieve the minimal effective concentration (MEC). The MEC will vary for each preparation but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma or tissue concentrations.
[0229] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or diminution of the disease state is achieved.
[0230] The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
[0231] in some embodiments, the humanized VHH antibodies and pharmaceutical compositions comprising them are administered to subjects suffering from psoriasis, particularly plaque psoriasis, more particularly mild to moderate plaque psoriasis, as a single treatment or as a treatment regimen that include at least one additional agent or treatment for psoriasis or at least one symptom associated with this disease. According to specific embodiments, the additional treatment includes steroids.
[0232] In certain embodiments, the additional agent or treatment is useful in the prevention and / or treatment of at least one a disease or disorder listed above.
[0233] The present invention provides kits comprising the compositions of the present invention suitable for injection and a syringe or an injection device.
[0234] Evaluating the activity and safety of the humanized VHH antibodies for use in therapy The humanized VHH antibodies and sets of humanized VHH antibodies of the present invention may be tested in vitro, in vivo and ex vivo for their activity in IL- 17 related disease models.In vitro disease models for psoriasis and atopic dermatitis were reviewed in Sarama et al., 2022. An in vitro tissue cross-reactivity (TCR) study may be used to identify non-specific and specific binding of the humanized VHH antibodies in different types of human tissues. This information is vital in ensuring that experimental antibodies do not bind to epitopes other than the targeted sites, thus minimizing the risk of treatment-related toxicity.
[0235] Some of the animal models utilizes animal or human skin. Human skin models, e.g., of psoriasis, utilizing cultures of primary human epidermal keratinocytes isolated from neonatal foreskin, may be used to evaluate the potential therapeutic effects of the humanized VHH antibodies. The effect of the humanized VHH antibodies of the present invention on factors regulating psoriatic keratinocytes (Zhou, X. et al. 2022) may also be tested.
[0236] As a nonlimitative example, an in vivo study in SCID / Beige mice transplanted with human xenograft (Keren et al., 2018) may be used to test several biological effects, specifically of IL-17 neutralization by the humanized VHH antibodies of the present invention. This model is considered a suitable in vivo model as normal human skin is engrafted into SCID mouse and disease is induced by injection of IL-2 activated PBMC's from human psoriatic patients. Blocking the cascade downstream of IL- 17 by the humanized VHH antibodies of the invention may be determined by measurement of the marker’s level (such as S100A7, Ki-67, beta-def ensin-2) and skin appearance as judged by H&E staining or qRT-PCR.
[0237] In an exemplary setup of this model, healthy human skin pieces are transplanted to SCID mice at day 0. Peripheral Blood Mononuclear Cells (PBMCs) from psoriatic patients’ blood are isolated and cultured in the presence of a high dose of IL-2 for 14 days to activate allogeneic T-cells expressing high levels of NK cells receptors. These PBMCs are injected to the mice on day 28 following the engraftment, generating psoriatic-like lesions which develop within the transplants, displaying almost all the key features of human psoriasis. These features include thickening of the epidermis, the presence of immune cells, edema, expanded blood vessels, and increased keratinocyte proliferation. Importantly, these psoriasis-like lesions respond to commonly used anti-psoriatic treatments. This highlights the significant relevance of this pre-clinical model for psoriasis research (Keren et al, 2018). Treatments with humanized VHH antibodies or with controls are done on day 42 while skin harvest and analysis is performed on day 56.Pre-clinical safety studies include, for example (i) human tissue cross reactivity (TCR) study (ii) pharmacokinetic / biodistribution (PK / BD) study in rats and (ii) a GLP toxicology study in suitable animals.
[0238] A GLP toxicology study may be used to confirm an acceptable safety profile of the tested humanized VHH antibody. The currently accepted toxicology animal model for mAbs against psoriasis is performed in non-human primates (NHP) as described for example in Kolbinger et al., 2022., but other animal models may be applied.
[0239] The phrase "subject in need thereof' used herein refers to a mammalian male or female subject (e.g., human being) who is diagnosed with an inflammatory disease or disorder. In a specific embodiment, this term encompasses individuals who are at risk to develop an inflammatory disease or disorder. The subject may be of any gender or at any age including neonatal, infant, juvenile, adolescent, adult and elderly adult.
[0240] As used herein the term “about” refers to ~ 10 %, ~5% or ~ 1% above or below the indicated value.
[0241] The terms "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to".
[0242] The term “consisting of‘ means “including and limited to”.
[0243] The term "consisting essentially of means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
[0244] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0245] Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosedsubranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0246] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging / ranges between” a first indicate number and a second indicate number and “ranging / ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
[0247] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
[0248] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments unless the embodiment is inoperative without those elements.
[0249] It is noted that each possibility disclosed throughout the specification represents a separate embodiment of the present invention.
[0250] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
[0251] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.EXAMPLES
[0252] Example 1: Production of VHH antibodies
[0253] VHH antibodies were cytoplasmically expressed as Hisl4-NEDD8 fusions in E. coli, captured on a Ni(II) chelate column, and eluted by NEDP1 -mediated tag-cleavage (Frey and Gbrlich, 2014; Pleiner et al., 2015). The structural disulfide bond was introduced after purification by treatment with DsbA, DsbC and oxidized glutathione, as disclosed in WO2024 / 256467, using 50°C as a final treatment temperature of the humanized variants. The treatment resulted in a quantitative disulfide-bonding as verified non-reducing SDS / PAGE after quenching free cysteines with iodoacetamide. As control, aliquots were left untreated in order to determine their melting points (Tms) in the reduced, i.e. non-disulfide-bonded state.
[0254] Example 2: Kinetic measurements of affinity by biolayer interferometry (BLI)
[0255] For affinity measurements, human IL-17A and IL-17F were produced as secreted proteins in human Expi293F cells (Thermo Fisher Scientific). The polypeptides contained an N-terminal cleavable secretion signal, and at their C-terminus a Tev-cleavage site, followed by a rabbit Fc fragment, an Avi-tag for enzymatic biotinylation with BirA and ATP (Beckett et al., 1999), and a Hise tag. The Hise tag was used for purification by Ni(II) chelate chromatography.
[0256] 100 nM biotinylated IL- 17 in assay buffer (50 mM Tris / HCl pH 7.5, 150mMNaCl, 0.02% Tween 20 and 0.1% BSA) was bound to a binding threshold of 3 nm to High Precision Streptavidin biosensors of an Octet RED96e instrument (ForteBio / Sartorius). The sensors were then subjected to three 10 minutes washes with assay buffer, with assay buffer with increased salt (1000 mM NaCl) and supplemented with 1 mM biotin, and with assay buffer again. These steps were required to free the sensors from any loosely bound bait whose slow release would otherwise bias the measurement towards high dissociation rates. Indicated concentrations (10, 20, and 40 nM) of indicated VHH antibodies were allowed to bind their target for 1800 seconds and to dissociate for another 1200 seconds, each in assay buffer. Binding and dissociation were recorded as wavelength shifts (in nm). Baselines were recorded by measuring a ‘minus VHH control’ in parallel. On-rates, off-rates, and dissociation constants (KDS) were calculated using the Octet Data Analysis HT 12.0 software by fitting a mass transport model to the data. The results are demonstrated in Figures 2A-2M and 3A-3M and are summarized in Table 3. As can be seen, thehumanized VHH antibodies bind IL-17A and IL-17F with picomolar to sub-nanomolar affinities respectively.
[0257] Example 3. Testing the stability of the VHH antibodies
[0258] For the intended therapeutic application, the IL- 17 VHH antibodies should not only bind their targets with high affinity, but also, they should be developable as biological drugs. This includes that they are stable enough to survive a lengthy, large-scale production process as well as transportation and storage (ideally for years in formulation) without aggregation or loss of activity.
[0259] A good predictor for stability is thermostability, which can be measured, e.g., by thermal shift assays or specifically by differential scanning fluorimetry (Goldberg et al., 2011). The method exploits that melting (thermal unfolding) of a protein exposes aromatic / hydrophobic residues (from its hydrophobic core), which then bind and enhance the fluorescence of the added SYPRO Orange dye.
[0260] VHH antibodies were subjected to differential scanning fluorimetry (DSF). Assays were performed in a volume of 20 pl, at 1 mg / ml VHH concentration in 50 mM Tris / HCl, 150 mM NaCl (pH 8.0 at 20°C), and lx SYPRO Orange dye (diluted from a 5000x stock; Life Technologies). The plate was sealed with transparent MicroSeal® ‘B’ Seal (Bio-Rad), briefly centrifuged to remove any air bubbles, and placed onto a CFX96 Real-Time System (Cl 000 Thermal Cycler, BioRad). The samples were incubated for 5 min at 20°C. The temperature was then increased by 1°C every 45 seconds until 95°C was reached. Fluorescence was measured at the end of each step with 532 nm excitation and a 555 nm long pass filter. Melting temperatures are defined as the inflection point of the first melting peak. If the melting peak remained lower than the initial fluorescence at 20°C, then this was interpreted as if no melting had occurred. As shown in Figures 4A-4M, compared to the starting VHH Re42B04 (Tm = 40°C), the humanized versions show an increased stability in their reduced states (Tm ~46-50°C). In their disulfide-bonded state, a shift from a Tm of 59°C to hyperthermostability (Tm >95°C) was observed.
[0261] Example 4. Cell-based IL-17 stimulation assay and measurement of reporter activity To monitor the biological activity of IL-17 variants in a cell-based system, a HEK-Blue™ IL-17 reporter cell line (Invivogen hkb-il 17) was used. These cells are HEK293 cells stably expressingthe human IL-17RA and IL-17RC receptors as well as the adapter Actl / TRAF3IP2. HEK-Blue™ IL-17 cells further encode a secreted embryonic alkaline phosphatase (SEAP) reporter controlled by a promoter with NF-kB and AP-1 binding sites. Upon binding of the IL-17 ligands to its receptors on the cell surface, NF-kB and AP-1 get activated, SEAP is produced and secreted into the cell supernatant. The amount of SEAP can be measured colorimetrically, using QUANTI-Blue™ as a substrate.
[0262] Cells were cultivated in DMEM medium supplemented with 10% (v / v) fetal bovine serum, 4.5 g / L glucose, 2 mM L-glutamine, 100 U / mL penicillin, 100 pg / mL streptomycin and 100 pg / mL Normocin™. Selection antibiotics (HEK-Blue™ Selection) were introduced after the second passage and the growth medium was renewed at least twice per week. Cells were passaged at 70-80% confluency by scraping in PBS and not cultivated longer than 20 passages.
[0263] To evaluate the cellular response, titration curves were conducted with the different IL-17 variants. For this, HEK-Blue™ IL-17 cells were seeded in 96-well plates in medium without selection antibiotics and stimulated with serial three-fold dilutions of IL-17A (produced in HEK cells, Proteintech HZ-1113), IL-17F (produced in HEK cells, Proteintech HZ-1116), or IL-17AF (produced in CHO cells, R&D systems 5837-IL-010). Medium without cells and untreated cells served as negative controls. After overnight incubation, 20 pl cell supernatant from each well was mixed with 180 pl QUANTLBlue™ solution in a separate 96-well plate and incubated for 30 min at 37°C. SEAP levels in the supernatant were determined by measuring the absorbance at 620 nm (OD620). The OD620 of the medium-only control served as the background and was subtracted from all sample wells. Each condition was assayed in triplicate. Induction was calculated from the ratio OD620 (sample) / OD620 (untreated). Based on the titration curves depicted in Figures 5A and 5B, compared to Figures 5B-5F, the cells are more responsive to IL-17A. Therefore, higher concentration of IL-17F and IL-17AF was used to achieve a comparable range of induction in the neutralization assays below.
[0264] Example 5. Cell-based IL-17 neutralization assay
[0265] To assess if the disclosed humanized anti-IL-17 VHH antibodies block the binding of IL-17 variants to their receptors, the inventors carried out cell-based neutralization assays using HEK-Blue™ IL-17 reporter cells. These cells express human IL-17RA and IL-17RC receptors as well as the adapter Actl . They secrete a phosphatase reporter in response to the receptor binding ofIL-17 variants. By quantitating the amount of secreted phosphatase, the activation of the IL-17 receptors can be measured as described in Example 4.
[0266] To test for neutralization, recombinant human IL-17A (5 ng / mL corresponding to 0.17 nM, Proteintech HZ-1113), IL-17F (25 ng / mL corresponding to 0.85 nM, Proteintech HZ-1116), or IL-17AF (25 ng / mL corresponding to 0.85 nM, R&D systems 5837-IL-010), were pre-incubated for two hours at 37°C under constant shaking with serial three-fold dilutions of VHH antibodies before being added to the reporter cells. Medium without cells, untreated cells, and cells treated with IL- 17 variants in the absence of any VHH served as controls. The stimulated cells were incubated over night at 37°C, 5% CO2 and then the reporter activity was measured as described in Example 4. The OD620 of “medium only” served as the background and was subtracted from all sample wells. Each condition was assayed in triplicate. Normalized induction was calculated from the ratio OD620 (sample) / OD620 (IL- 17 only). Figures 6A-6L provide plots demonstrating inhibition of the reporter’s expression following induction by IL-17A (Figures 6A-6D) or IL-17F (Figures 6E-6H) homodimers, or IL-17AF heterodimer (Figures 6i-6L) that had been preincubated with indicated concentrations of anti-IL-17 VHH antibodies. As shown, all tested humanized Re42B04 variants neutralize IL-17A at a lower mass concentration than sonelokimab, a trimer of nanobodies targeting IL-17A, IL-17F, and albumin (specifically shown in Figures 6B, 6F and 6J).
[0267] Example 6. Ex-vivo human skin model
[0268] InflammaSkin® is a psoriasis-like model developed by Genoskin to reproduce the key features of pro-Thl7 / Thl inflammation associated with psoriasis. The model, utilized and described in WO2024141567, relies on in-situ activation of resident T-cell of normal skin biopsies and their further polarization into Thl7 / Thl phenotype with the supplementation of a culture medium containing a cocktail of pro-inflammatory cytokines. This model has been successfully validated with topically applied compounds, including steroids, delivered either in a prophylactic or therapeutic manner.
[0269] The model is employed to evaluate the effective dose, and the dosing regimen prior to conducting in-vivo studies in mice transplanted with psoriatic human skin. The humanized VHH antibodies are compared to monoclonal antibody targeting IL-17A (i.e., Secukinumab) used clinically as subcutaneous injection for treatment of psoriasis, and to steroidal treatment with betamethasone.Skin samples from female donors, with no record of current inflammatory skin disease or treatment are cultured under standard cell culture conditions (CO2 incubator at 37°C, water saturation, daily medium renewal). Next, in situ activation and Thl7 / Thl polarization of skin resident T cells with pro-inflammatory cytokine cocktail is added to induce the psoriatic phenotype, followed by intradermal treatment with humanized VHH antibody, for example once on day 3 or thrice on days 3-5. Positive control groups include standard care of topical betamethasone, or daily prophylactic treatment or single subcutaneous administration of Secukinumab on day 3, while negative control treatments include irrelevant VHH antibody that does not bind IL- 17.
[0270] The anti-inflammatory effect is evaluated in a three-week to three-months follow-up period by measuring cytokine secretion, including IL-17 family cytokines, interferon 10 (IFN-10) and interferon y (IFN-y). Additionally, skin’s structure, integrity & viability are assessed by a histological analysis (e.g., Hematoxylin & Eosin staining).
[0271] REFERENCES
[0272] Abdiche Y, Malashock D, Pinkerton A, Pons J (2008) Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem, 377: 209-217
[0273] Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBSLett, 414: 521-526. doi: 10.1016 / 80014-5793(97)01062-4
[0274] Beckett D, Kovaleva E, Schatz PJ (1999) A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci, 8: 921-929
[0275] Su, S.; Esparza, T.J.; Nguyen, D.; Mastrogiacomo, S.; Kim, J.H.; Brody, D.L. Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. Int. J. Mol. Sci. 2021, 22, 8695
[0276] Glatt S, Baeten D, Baker T, Griffiths M, lonescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S (2018) Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis, 77: 523-532 Goepfert, A., Lehmann, S., Blank, J., Kolbinger, F., & Rondeau, J. M. (2020). Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling. Immunity, 52(3), 499-512. e5 Goldberg DS, Bishop SM, Shah AU, Sathish HA (2011) Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci, 100: 1306-1315Giittler T, Aksu M, Dickmanns A, Stegmann KM, Gregor K, Rees R, Taxer W, Rymarenko O, Schiinemann J, Dienemann C, Gunkel P, Mussil B, Krull J, Teichmann U, GroB U, Cordes VC, Dobbelstein M, Gbrlich D (2021) Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J, el07985
[0277] Keren A, Shemer A, Ginzburg A, Ullmann Y, Schrum AG, Paus R, Gilhar A. Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. J Allergy Clin Immunol.
[0278] 2018 Jul;142(l):305-308
[0279] Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. Mclnnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, Jose M. Carballido, Peter Hausermann, Claudio Calender, Beate Vogel, Jean-Michel Rondeau, Gerard Bruin, Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety, Pharmacology & Therapeutics, Volume 229, 2022, 107925,
[0280] Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature, 363: 446-448. doi: 10.1038 / 363446a0
[0281] Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE SG, FIXTURE SG (2014) Secukinumab in plaque psoriasis— results of two phase 3 trials. N Engl J Med, 371: 326- 338
[0282] Mease PJ, Mclnnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE SG (2015) Secukinumab Inhibition of Interleukin- 17A in Patients with Psoriatic Arthritis. NEngl J Med, 373: 1329- 1339
[0283] Mills KHG (2022) IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol, 1-17
[0284] Nies JF, Panzer U (2020) IL-17C / IL-17RE: Emergence of a Unique Axis in TH17 Biology. Front Immunol, 11: 341
[0285] Papp KA, Weinberg MA, Morris A, Reich K (2021) IL17A / F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet, 397: 1564-1575
[0286] Overview of 3Rs opportunities in drug discovery and development using non-human primates, Drug Discovery Today: Disease Models, Volume 23, 2017, Pages 11-16,
[0287] Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A (2021) Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med, 385: 142-152
[0288] Rossotti MA, Belanger K, Henry KA, Tanha J (2022) Immunogenicity and humanization of single-domain antibodies. FEBS J, 289: 4304-4327. doi: 10.1111 / febs.15809
[0289] Sarama et al., Frontiers in Bioengineering and Biotechnology February 2022 | Volume 10 | Article 803218.Skroza N, Proietti I, Bernardini N, Aquila E, Balduzzi V, La Viola G, Mambrin A, Muscianese M, Tolino E, Zuber S, Potenza C, Ferrazza P (2017) 11-17 and Its Role in Psoriasis, Hidradenitis Suppurativa And Acne. Internal Medicine and Care, 1(2): 1-6
[0290] Su, S.; Esparza, T.J.; Nguyen, D.; Mastrogiacomo, S.; Kim, J.H.; Brody, D.L. Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. Int. J. Mol. Sci. 2021, 22, 8695.
[0291] Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K (2021) Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med, 385: 130-141
[0292] Wilson SC, Caveney NA, Yen M, Pollmann C, Xiang X, Jude KM, Hafer M, Tsutsumi N, Piehler J, Garcia KC (2022) Organizing structural principles of the IL- 17 ligand-receptor axis. Nature, 609: 622-629
[0293] Zhang Y. Huo M. Zhou J. Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010; 99: 306-314
[0294] Zhou, X. et al. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. 2022;
[0295] Cell Death Dis 13, 81
Claims
CLAIMS1. A VHH antibody that is a humanized or partially humanized variant of SEQ ID NO. 1, that comprises 2-13 substitutions selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, Y112X wherein X is selected from Y, H, V, E, S, and T, L115Q, and QI 18L to SEQ ID NO. 1, wherein the VHH antibody binds to human IL-17A and human IL- 17F and inhibits IL- 17 receptor activation.
2. A humanized or partially humanized VHH antibody that binds to human IL-17A and human IL-17F and inhibits IL-17 receptor activation, wherein the VHH antibody comprises an amino acid sequence selected from SEQ ID NOs. 2-13, or a variant thereof having at least 95% identity with any of these sequences, wherein positions 62 and 63 are D S.
3. The humanized or partially humanized VHH antibody according to claim 1 or 2, comprising the CDR3 sequence NDMPYGLDTRMDEYEXW (SEQ ID NO. 22) wherein X is selected from Y, H, V, E, S, and T.
4. The humanized or partially humanized VHH antibody of any one of claims 1-3 comprising a set of 3 CDR sequences wherein, CDR1 comprises SEQ ID NO. 14 or SEQ ID NO. 23, CDR2 comprises SEQ ID NO. 15, and CDR3 comprises a sequence selected from SEQ ID NOs. 16- 21.
5. The humanized or partially humanized VHH antibody of any one of claims 1-4, comprising a sequence selected from SEQ ID NOs. 2-13.
6. The humanized or partially humanized VHH antibody of claim 5 consisting of an amino acid sequence selected from SEQ ID NOs. 2-13.
7. The humanized or partially humanized VHH antibody according to claim 1 or 2, comprising at least two substitutions selected from Q1E, V14P, E23A, H62D, F63S, A75S, H80Y, D84N, K87R, P88A, Y112X, L115Q, Q118L to SEQ ID NO. 1 (Re42B04), wherein X is selected from H, V, E, S, or T.
8. The humanized or partially humanized VHH antibody according to claim 1, comprising the substitutions H62D and F63S to SEQ ID NO. 1.
9. The humanized or partially humanized VHH antibody variant according to claim 1 wherein position 1 of SEQ ID NO. 1 is Q or E, position 14 is V or P, position 23 is E or A, position 62 is D, position 63 is S, position 75 is A or S, position 80 is H or Y, position 84 is D or N, position 87 is K or R, position 88 is P or A, position 112 is selected from Y, H, V, E, S, and T, position 115 is Q, and position 118 is Q or L.
10. The humanized or partially humanized VHH antibody according to any one of claims 1-9, selected from Re42B04Human0 (SEQ ID NO. 2), Re42B04Humanl (SEQ ID NO. 3), Re42B04Human2 (SEQ ID NO. 4), Re42B04Human3 (SEQ ID NO. 5), Re42B04Human4 (SEQ ID NO. 6), Re42B04Human5 (SEQ ID NO. 7), Re42B04Human6 (SEQ ID NO. 8), Re42B04Human7 (SEQ ID NO. 9), Re42B04Human8 (SEQ ID NO. 10), Re42B04Human9 (SEQ ID NO. 11), Re42B04Humanl0 (SEQ ID NO. 12), Re42B04Humanl 1 (SEQ ID NO.13), or a VHH antibody, which is a variant thereof having at least 99% identity to any of said sequences.
11. The humanized or partially humanized VHH antibody according to any one of the preceding claims, which is conjugated or fused to a heterologous moiety.
12. The humanized or partially humanized VHH antibody according to any one of the preceding claims, having in a monomeric form, a binding affinity expressed as a dissociation constant KD, to an immobilized human IL-17A of 500 pM, 300 pM, 200 pM, 150 pM, or less, and to immobilized IL-17F homodimer of 5 nM, 2 nM, 1 nM, 500 pM, 300 pM, or less.
13. The humanized or partially humanized VHH antibody according to any one of the preceding claims, which is thermostable or hyperthermostable having a melting temperature of at least about 65°C, of at least about 80°C, of at least 90°C or of at least about 95°C when measured in disulfide-bonded form and under non-reducing conditions.
14. A nucleic acid molecule encoding a humanized or partially humanized VHH antibody according to any one of the preceding claims.
15. A recombinant cell or a non-human organism transformed or transfected with the nucleic acid molecule of claim 14 or with a vector comprising said nucleic acid molecule.
16. The recombinant cell of claim 15, selected from a bacterium cell, a yeast cell, an insect cell, a mammalian cell, and a plant cell.
17. A method for recombinant production of a humanized or partially humanized VHH antibody according to any one of claims 1-11, comprising cultivating cells or an organism in a suitable medium and obtaining the VHH antibody from the cells or organism or from the medium.
18. A pharmaceutical composition comprising a humanized or partially humanized VHH antibody according to any one of claims 1-11, and a pharmaceutically acceptable salt, excipient, or diluent.
19. The pharmaceutical composition of claim 18, formulated for parenteral administration.
20. The pharmaceutical composition of claim 18, formulated for local administration, in particular for topical administration.
21. The pharmaceutical composition of any one of claims 18-20, for use in the prevention or treatment of a disease or disorder caused by or associated with an activity or overactivity of IL-17A and / or IL-17F.
22. The pharmaceutical composition for use of claim 21, wherein the disease or disorder is an inflammatory and / or immune-related disorder, or an infectious disease.
23. The pharmaceutical composition for use of claim 22, wherein the inflammatory and / or immune-related disease or disorder is selected from psoriasis, arthritis, asthma, hidradenitis suppurativa, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), multiple sclerosis, skin cancer, ankylosing spondylitis, uveitis, atopic dermatitis, graft versus host disease, Alzheimer’s disease, fatty liver disease, sepsis, ischemic stroke, Parkinson’s disease, active non-radiographic axial spondylarthritis with objective clinical signs of inflammation, systemic lupus erythematosus (SLE), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hidradenitis suppurative (HS), pemphigus vulgaris (PV), pityriasis rubra pilaris (PRP), alopecia areata, systemic sclerosis, lichen planus, and impetigo herpetiformis.
24. The pharmaceutical composition for use of claim 22, wherein the inflammatory and / or immune-related disease or disorder is an autoimmune disease selected from psoriasis, arthritis, systemic lupus erythematosus (SLE), familial mediterranean fever, and inflammatory bowel disease (IBD).
25. The pharmaceutical composition for use of claim 22, wherein the inflammatory and / or immune-related disease or disorder is a skin disorder.
26. The pharmaceutical composition for use of claim 25, wherein the disease is psoriasis, particularly plaque psoriasis, moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, or pustular psoriasis.
27. The pharmaceutical composition for use of claim 24, wherein the disease is arthritis, particularly rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or enthesitis- related arthritis.
28. A method for the prevention or treatment of a disease or disorder caused by and / or associated with an activity or overactivity of IL-17A and / or IL-17F, the method comprising administering to a subject in need thereof an effective dose of a humanized or partially humanized VHHantibody of any one of claims 1-11, or a pharmaceutical composition of any one of claims 18- 20.
29. The method of claim 28, wherein the disease or disorder is an inflammatory and / or immune- related disease or disorder, or an infectious disease.
30. The method of claim 29, wherein the inflammatory and / or immune-related disease or disorder is an autoimmune disease selected from psoriasis, arthritis, systemic lupus erythematosus (SLE), familial mediterranean fever, and inflammatory bowel disease (IBD).
31. The method of claim 29, wherein the inflammatory and / or immune-related disease or disorder is a skin disease or disorder.
32. The method of claim 31, wherein the disorder is psoriasis, particularly plaque psoriasis, moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, or pustular psoriasis.
33. The method of claim 29, wherein the disease or disorder is arthritis, particularly rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or enthesitis-related arthritis.
34. The method of claim 29, wherein the infectious disease is a viral, bacterial, or fungal disease.
35. The method of any one of claims 28-34, wherein the composition is administered parentally or locally.
